Hong Kong, 29 November 2021 – Despite the on-going COVID-19 pandemic, 2021 marked few key milestones of Avalon’s Diagnostics Division. Emerging Viral Diagnostics (“EVDL”), a subsidiary of Avalon BioMedical Management (“Avalon Group”), celebrated the opening of its first production workshop in Hong Kong on 20 July, 2021.

EVDL’s Automated Multiplex Diagnostic System (the “System”) is composed of three major elements: analytical device, microfluidic cartridge and control software. The workshop in Hong Kong will be dedicated for manufacturing the analytical device and setting up the control PC of the System. It will also serve as EVDL’s Research and Development hub in Hong Kong.

Back in February 2020, Avalon Group entered into a co-operation framework agreement with the People’s Government of Pingshan District, Shenzhen, Guangdong Province, China and Xiangxue Pharmaceutical (“Xiangxue”). Under the framework, the three parties had jointly established a company focusing in research, development, production and sale of public health materials in Pingshan District.

Avalon’s family celebrating this important milestone together.

Recently, the setup of production plant in Pingshan has completed. Phase 1 of the plant covers an area of 3,000 square meters, including 1,000 square meters of high standard cleanroom, and the plant can be further expanded to 6,000 square meters. This plant will serve as one of the production sites of the microfluidic cartridge of the System, as well as Biochemistry laboratory.

“Scientists can do technological research and development well in Hong Kong, but when it comes to mass-scale production and industrialization, Shenzhen definitely has its competitive edge. The journey from scientific research to industrialization demonstrates a good collaboration between Shenzhen and Hong Kong,” said Dr. Terence Lau to the reporter of SZTV News, Shenzhen Satellite TV.

(Photo from SZTV News, Shenzhen Satellite TV)

All plants, both in Hong Kong and in Pingshan, target to obtain ISO 13485 certification for production of medical device and Avalon is confident that pilot production will be in full force starting 2022 Q2. These production sites are the landmarks of successful translation of scientific university research to industrialization. EVDL is devoted to bringing the System to commercialization and have more of the company’s vision come true in the near future.

Check out the recent media coverage below:
https://www.dutenews.com/p/6316225.html
https://mp.weixin.qq.com/s/xub4s_xTmFvn4KYJGEu9IQ